Related references
Note: Only part of the references are listed.Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
Tara C. Anderson et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2022)
Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
Hector S. Izurieta et al.
CLINICAL INFECTIOUS DISEASES (2021)
Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older
Bradley Ackerson et al.
VACCINE (2021)
An early look at the second dose completion of the recombinant zoster vaccine in Canadian adults: A retrospective database study
Ashleigh McGirr et al.
VACCINE (2021)
Insurance reimbursements for recombinant zoster vaccine in the private sector
Andrew J. Leidner et al.
VACCINE (2021)
Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019
Beth I. Wallace et al.
JAMA NETWORK OPEN (2021)
Surveillance of Vaccination Coverage Among Adult Populations - United States, 2018
Peng-Jun Lu et al.
MMWR SURVEILLANCE SUMMARIES (2021)
A systematic literature review of the recombinant subunit herpes zoster vaccine use in immunocompromised 18-49 year old patients
Etienne Racine et al.
VACCINE (2020)
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States
Manish Patel et al.
EMERGING INFECTIOUS DISEASES (2020)
Neurological and Ophthalmological Manifestations of Varicella Zoster Virus
Sachin Kedar et al.
JOURNAL OF NEURO-OPHTHALMOLOGY (2019)
Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) — United States, October 2017–June 2018
Elisabeth M. Hesse et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2019)
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study
Himal Lal et al.
VACCINE (2018)
Burden of herpes zoster in 16 selected immunocompromised populations in England: a cohort study in the Clinical Practice Research Datalink 2000-2012
Emad A. Yanni et al.
BMJ OPEN (2018)
Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines
Kathleen L. Dooling et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2018)
Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals
Juliana L. Meyers et al.
VACCINE (2018)
Incidence of herpes zoster amongst adults varies by severity of immunosuppression
Carsten Schroeder et al.
JOURNAL OF INFECTION (2017)
Herpes Zoster
Kenneth Schmader
CLINICS IN GERIATRIC MEDICINE (2016)
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older
A. L. Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases Implications for Vaccination
Huifeng Yun et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults
Himal Lal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Incidence of herpes zoster in patients with altered immune function
S-Y. Chen et al.
INFECTION (2014)
Herpes Zoster
Jeffrey I. Cohen
NEW ENGLAND JOURNAL OF MEDICINE (2013)
A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy
Dora Liu et al.
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2013)
The impact of herpes zoster and post-herpetic neuralgia on quality-of-life
Robert W. Johnson et al.
BMC MEDICINE (2010)
Postherpetic neuralgia in the elderly
R. W. Johnson et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Herpes zoster ophthalmicus - Natural history, risk factors, clinical presentation, and morbidity
Thomas J. Liesegang
OPHTHALMOLOGY (2008)
Herpes zoster
JW Gnann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
